Skip to content
2000
Volume 33, Issue 8
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Background

Geranyl acetate, a compound found in plant oils, has been studied for its potential effects on renal and cardiovascular ailments.

Objective

This study aimed to investigate the diuretic and anti-hyperuricemic properties of geranyl acetate in male Wistar rats using a hyperuricemia-induced rat model.

Methods

Molecular docking studies were conducted to assess geranyl acetate's interactions with various targets. studies were performed to evaluate its scavenging ability and inhibition of xanthine oxidase, urease, and acetylcholinesterase. Subsequently, we administered different doses of geranyl acetate (25, 50, and 100 mg/kg) and a reference drug (furosemide) to the rats to assess their acute and repeated dose diuretic effects over seven days. To understand the diuretic mechanism, we used inhibitors, such as L- NAME, indomethacin, and atropine, prior to administering geranyl acetate. We also tested the anti-hyperuricemic potential of geranyl acetate on hyperuricemic rats.

Results

Molecular docking suggested strong binding between geranyl acetate and nitric oxide synthase. studies showed significant free radical scavenging activity and and inhibition of acetylcholinesterase, xanthine oxidase, and urease. The 100 mg/kg dose exhibited the most promising diuretic effects, with nitric oxide appearing to influence its action. Uric acid excretion increased at this dose, resembling allopurinol effects.

Conclusion

Geranyl acetate has demonstrated significant diuretic and anti-hyperuricemic effects, likely influenced by nitric oxide release and inhibition of enzymes, like xanthine oxidase and urease. The findings have suggested potential benefits for individuals with kidney ailments, hypertension, and gout.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673300632240823061848
2024-09-04
2026-03-11

  • From This Site

    /content/journals/cmc/10.2174/0109298673300632240823061848
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. KovesdyC.P. Epidemiology of chronic kidney disease: An update 2022.Kidney Int. Suppl.202212171110.1016/j.kisu.2021.11.00335529086
     [Google Scholar]
  2. KjeldsenS.E. Hypertension and cardiovascular risk: General aspects.Pharmacol. Res.2018129959910.1016/j.phrs.2017.11.00329127059
     [Google Scholar]
  3. LevinA. ChaudhryM.R. DjurdjevO. BeaulieuM. KomendaP. Diabetes, kidney disease and cardiovascular disease patients. Assessing care of complex patients using outpatient testing and visits: Additional metrics by which to evaluate health care system functioning.Nephrol. Dial. Transplant.20092492714272010.1093/ndt/gfp18019395415
     [Google Scholar]
  4. HenryR.M.A. KostenseP.J. BosG. DekkerJ.M. NijpelsG. HeineR.J. BouterL.M. StehouwerC.D.A. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study.Kidney Int.20026241402140710.1111/j.1523‑1755.2002.kid571.x12234312
     [Google Scholar]
  5. NishizawaH. MaedaN. ShimomuraI. Impact of hyperuricemia on chronic kidney disease and atherosclerotic cardiovascular disease.Hypertens. Res.202245463564010.1038/s41440‑021‑00840‑w35046512
     [Google Scholar]
  6. AliN. PerveenR. RahmanS. MahmoodS. RahmanS. IslamS. HaqueT. SumonA.H. KathakR.R. MollaN.H. IslamF. MohantoN.C. NurunnabiS.M. AhmedS. RahmanM. Prevalence of hyperuricemia and the relationship between serum uric acid and obesity: A study on Bangladeshi adults.PLoS One20181311e020685010.1371/journal.pone.020685030383816
     [Google Scholar]
  7. KoziołA. StryjewskaA. LibrowskiT. SałatK. GawełM. MoniczewskiA. LochyńskiS. An overview of the pharmacological properties and potential applications of natural monoterpenes.Mini Rev. Med. Chem.201514141156116810.2174/138955751466614112714582025429661
     [Google Scholar]
  8. GonçalvesM.J. CruzM.T. TavaresA.C. CavaleiroC. LopesM.C. CanhotoJ. SalgueiroL. Composition and biological activity of the essential oil from Thapsia minor, a new source of geranyl acetate.Ind. Crops Prod.201235116617110.1016/j.indcrop.2011.06.030
     [Google Scholar]
  9. QiF. YanQ. ZhengZ. LiuJ. ChenY. ZhangG. Geraniol and geranyl acetate induce potent anticancer effects in colon cancer Colo-205 cells by inducing apoptosis, DNA damage and cell cycle arrest.J. BUON201823234635229745075
     [Google Scholar]
  10. Quintans-JúniorL. MoreiraJ.C.F. PasqualiM.A.B. RabieS.M.S. PiresA.S. SchröderR. RabeloT.K. SantosJ.P.A. LimaP.S.S. CavalcantiS.C.H. AraújoA.A.S. QuintansJ.S.S. GelainD.P. Antinociceptive activity and redox profile of the monoterpenes.ISRN Toxicol.2013201311110.1155/2013/45953023724298
     [Google Scholar]
  11. MorettiM.D.L. PeanaA.T. SattaM. A study on anti-inflammatory and peripheral analgesic action of Salvia sclarea oil and its main components.J. Essent. Oil Res.19979219920410.1080/10412905.1997.9699459
     [Google Scholar]
  12. Plata-RuedaA. MartínezL.C. RolimG.S. CoelhoR.P. SantosM.H. TavaresW.S. ZanuncioJ.C. SerrãoJ.E. Insecticidal and repellent activities of Cymbopogon citratus (Poaceae) essential oil and its terpenoids (citral and geranyl acetate) against Ulomoides dermestoides. Crop. Prot.202013710529910.1016/j.cropro.2020.105299
     [Google Scholar]
  13. ShahG. ShriR. PanchalV. SharmaN. SinghB. MannA.S. Scientific basis for the therapeutic use of Cymbopogon citratus, stapf (Lemon grass).J. Adv. Pharm. Technol. Res.2011213810.4103/2231‑4040.7979622171285
     [Google Scholar]
  14. SahibN.G. AnwarF. GilaniA.H. HamidA.A. SaariN. AlkharfyK.M. Coriander (Coriandrum sativum L.): A potential source of high-value components for functional foods and nutraceuticals-a review.Phytother. Res.201327101439145610.1002/ptr.489723281145
     [Google Scholar]
  15. Food Chemicals Codex. Committee on food protection national research council. national academy os sciences, Washington D.C.1972Available From: https://law.resource.org/pub/us/cfr/ibr/004/nas.food.1972.pdf
  16. National Toxicology Program. NTP carcinogenesis studies of food grade geranyl acetate (71% geranyl acetate, 29% citronellyl acetate) (CAS No. 105-87-3) in F344/N rats and B6C3F1 mice (gavage study). Natl. Toxicol. Program Tech. Rep. Ser.1987252116212748693
     [Google Scholar]
  17. KimS. ThiessenP.A. BoltonE.E. ChenJ. FuG. GindulyteA. HanL. HeJ. HeS. ShoemakerB.A. WangJ. YuB. ZhangJ. BryantS.H. PubChem substance and compound databases.Nucleic Acids Res.201644D1D1202D121310.1093/nar/gkv95126400175
     [Google Scholar]
  18. SussmanJ.L. LinD. JiangJ. ManningN.O. PriluskyJ. RitterO. AbolaE.E. Protein Data Bank (PDB): Database of three-dimensional structural information of biological macromolecules.Acta Crystallogr. D Biol. Crystallogr.19985461078108410.1107/S090744499800937810089483
     [Google Scholar]
  19. HoldenJ.K. LimN. PoulosT.L. Identification of redox partners and development of a novel chimeric bacterial nitric oxide synthase for structure activity analyses.J. Biol. Chem.201428942294372944510.1074/jbc.M114.59516525194416
     [Google Scholar]
  20. ToyodaY. MorimotoK. SunoR. HoritaS. YamashitaK. HirataK. SekiguchiY. YasudaS. ShiroishiM. ShimizuT. UrushibataY. KajiwaraY. InazumiT. HottaY. AsadaH. NakaneT. ShiimuraY. NakagitaT. TsugeK. YoshidaS. KuribaraT. HosoyaT. SugimotoY. NomuraN. SatoM. HirokawaT. KinoshitaM. MurataT. TakayamaK. YamamotoM. NarumiyaS. IwataS. KobayashiT. Ligand binding to human prostaglandin E receptor EP4 at the lipid-bilayer interface.Nat. Chem. Biol.2019151182610.1038/s41589‑018‑0131‑330510193
     [Google Scholar]
  21. MaedaS. XuJ. N KadjiF.M. ClarkM.J. ZhaoJ. TsutsumiN. AokiJ. SunaharaR.K. InoueA. GarciaK.C. KobilkaB.K. Structure and selectivity engineering of the M1 muscarinic receptor toxin complex.Science2020369650016116710.1126/science.aax251732646996
     [Google Scholar]
  22. NishinoT. OkamotoK. KawaguchiY. MatsumuraT. EgerB.T. PaiE.F. NishinoT. The C-terminal peptide plays a role in the formation of an intermediate form during the transition between xanthine dehydrogenase and xanthine oxidase.FEBS J.2015282163075309010.1111/febs.1327725817260
     [Google Scholar]
  23. ZuevaI. DiasJ. LushchekinaS. SemenovV. MukhamedyarovM. PashirovaT. BabaevV. NachonF. PetrovaN. NurullinL. ZakharovaL. IlyinV. MassonP. PetrovK. New evidence for dual binding site inhibitors of acetylcholinesterase as improved drugs for treatment of Alzheimer’s disease.Neuropharmacology201915513114110.1016/j.neuropharm.2019.05.02531132435
     [Google Scholar]
  24. CunhaE.S. ChenX. Sanz-GaiteroM. MillsD.J. LueckeH. Cryo-EM structure of Helicobacter pylori urease with an inhibitor in the active site at 2.0 Å resolution.Nat. Commun.202112123010.1038/s41467‑020‑20485‑633431861
     [Google Scholar]
  25. VilarS. CozzaG. MoroS. Medicinal chemistry and the molecular operating environment (MOE): Application of QSAR and molecular docking to drug discovery.Curr. Top. Med. Chem.20088181555157210.2174/15680260878678662419075767
     [Google Scholar]
  26. SaleemU. ShehzadA. ShahS. RazaZ. ShahM.A. BibiS. ChauhdaryZ. AhmadB. Antiparkinsonian activity of Cucurbita pepo seeds along with possible underlying mechanism.Metab. Brain Dis.20213661231125110.1007/s11011‑021‑00707‑633759084
     [Google Scholar]
  27. BibiS. HasanM.M. WangY.B. PapadakosS.P. YuH. Cordycepin as a promising inhibitor of SARS-CoV-2 RNA dependent RNA polymerase (RdRp).Curr. Med. Chem.202229115216210.2174/1875533XMTE3xNDEq034420502
     [Google Scholar]
  28. DainaA. MichielinO. ZoeteV. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules.Sci. Rep.2017714271710.1038/srep4271728256516
     [Google Scholar]
  29. SanderT. FreyssJ. von KorffM. RufenerC. DataWarrior: An open-source program for chemistry aware data visualization and analysis.J. Chem. Inf. Model.201555246047310.1021/ci500588j25558886
     [Google Scholar]
  30. SadiaS. KhanU. SomiaG. ZeeshanA.S. SyedF.Z. MehreenL. Evaluation of in vitro antioxidant capacity and reducing potential of polyherbal drug Entoban.Afr. J. Pharm. Pharmacol.2015294098298710.5897/AJPP2015.4349
     [Google Scholar]
  31. KhanI.U. Carbonic anhydrase and urease inhibitory effects of Sonchus Asper. Life Sci. J.201310110.1055/a‑1908‑0935
     [Google Scholar]
  32. SweeneyA.P. WyllieS.G. ShallikerR.A. MarkhamJ.L. Xanthine oxidase inhibitory activity of selected Australian native plants.J. Ethnopharmacol.2001752-327327710.1016/S0378‑8741(01)00176‑311297862
     [Google Scholar]
  33. HameedB.J. ShariF.H. RamadhanU.H. Anti-hyperuricemic, uricosuric and xanthine-oxidase inhibitory activities of Watermelon powder in a rat gout model.Pharm. Biol.2010481376138310.3109/13880209.2010.48352120738177
     [Google Scholar]
  34. MendelsohnL.D. ChemDraw 8 ultra, windows and macintosh versions.J. Chem. Inf. Comput. Sci.20044462225222610.1021/ci040123t
     [Google Scholar]
  35. BibiS. SakataK. Current status of computer-aided drug design for type 2 diabetes.Curr. Computeraided Drug Des.201612216717710.2174/157340991266616042612070927113465
     [Google Scholar]
  36. KhanM. PatujoJ. MushtaqI. IshtiaqA. TahirM.N. BibiS. KhanM.S. ullahN. MustafaG. MirzaB. BadshahA. MurtazaI. Anti-diabetic potential, crystal structure, molecular docking, DFT, and optical-electrochemical studies of new dimethyl and diethyl carbamoyl-N, N′-disubstituted based thioureas.J. Mol. Struct.2022125313220710.1016/j.molstruc.2021.132207
     [Google Scholar]
  37. CattoM. PisaniL. LeonettiF. NicolottiO. PesceP. StefanachiA. CellamareS. CarottiA. Design, synthesis and biological evaluation of coumarin alkylamines as potent and selective dual binding site inhibitors of acetylcholinesterase.Bioorg. Med. Chem.201321114615210.1016/j.bmc.2012.10.04523199476
     [Google Scholar]
  38. LipinskiC.A. LombardoF. DominyB.W. FeeneyP.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X (96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1.Adv. Drug Deliv. Rev.2001461-332610.1016/S0169‑409X(00)00129‑011259830
     [Google Scholar]
  39. VeberD.F. JohnsonS.R. ChengH.Y. SmithB.R. WardK.W. KoppleK.D. Molecular properties that influence the oral bioavailability of drug candidates.J. Med. Chem.200245122615262310.1021/jm020017n12036371
     [Google Scholar]
  40. StanzioneF. GiangrecoI. ColeJ.C. Use of molecular docking computational tools in drug discovery.Prog. Med. Chem.20216027334310.1016/bs.pmch.2021.01.00434147204
     [Google Scholar]
  41. ZeferinoR.C.F. PiaiaV.A.A. OrsoV.T. PinheiroV.M. ZanettiM. ColpaniG.L. PadoinN. SoaresC. FioriM.A. RiellaH.G. Synthesis of geranyl acetate by esterification of geraniol with acetic anhydride through heterogeneous catalysis using ion exchange resin.Chem. Eng. Res. Des.202116815616810.1016/j.cherd.2021.01.031
     [Google Scholar]
  42. AndreadouI. SchulzR. PapapetropoulosA. TuranB. YtrehusK. FerdinandyP. DaiberA. Di LisaF. The role of mitochondrial reactive oxygen species, NO and H2 S in ischaemia/reperfusion injury and cardioprotection.J. Cell. Mol. Med.202024126510652210.1111/jcmm.1527932383522
     [Google Scholar]
  43. DaenenK. AndriesA. MekahliD. Van SchepdaelA. JouretF. BammensB. Oxidative stress in chronic kidney disease.Pediatr. Nephrol.201934697599110.1007/s00467‑018‑4005‑430105414
     [Google Scholar]
  44. LeeH. JoseP.A. Coordinated contribution of NADPH oxidase-and mitochondria-derived reactive oxygen species in metabolic syndrome and its implication in renal dysfunction.Front. Pharmacol.20211267007610.3389/fphar.2021.67007634017260
     [Google Scholar]
  45. Gonzalez-VicenteA. HongN. GarvinJ.L. Effects of reactive oxygen species on renal tubular transport.Am. J. Physiol. Renal Physiol.20193172F444F45510.1152/ajprenal.00604.201831215804
     [Google Scholar]
  46. WangW. KangP.M. Oxidative stress and antioxidant treatments in cardiovascular diseases.Antioxidants2020912129210.3390/antiox912129233348578
     [Google Scholar]
  47. SchlickmannF. BoeingT. MarianoL.N.B. da SilvaR.C.M.V.A. da SilvaL.M. de AndradeS.F. de SouzaP. Cechinel-FilhoV. Gallic acid, a phenolic compound isolated from Mimosa bimucronata (DC) Kuntze leaves, induces diuresis and saluresis in rats.Naunyn Schmiedebergs Arch. Pharmacol.2018391664965510.1007/s00210‑018‑1502‑829663016
     [Google Scholar]
  48. PandeyM. SinghA. AgnihotriN. KumarR. SahaP. PandeyR.P. KumarA. Clinical pharmacology & therapeutic uses of diuretic agents: A review.J. Res. Appl. Sci. Biotechnol.20221112010.55544/jrasb.1.3.3
     [Google Scholar]
  49. TitkoT. PerekhodaL. DrapakI. TsapkoY. Modern trends in diuretics development.Eur. J. Med. Chem.202020811285510.1016/j.ejmech.2020.11285533007663
     [Google Scholar]
  50. ShaitoA. ThuanD.T.B. PhuH.T. NguyenT.H.D. HasanH. HalabiS. AbdelhadyS. NasrallahG.K. EidA.H. PintusG. Herbal medicine for cardiovascular diseases: Efficacy, mechanisms, and safety.Front. Pharmacol.20201142210.3389/fphar.2020.0042232317975
     [Google Scholar]
  51. van WykA.S. PrinslooG. Health, safety and quality concerns of plant-based traditional medicines and herbal remedies.S. Afr. J. Bot.2020133546210.1016/j.sajb.2020.06.031
     [Google Scholar]
  52. AlotaibiB.S. IjazM. BuabeidM. KharabaZ.J. YaseenH.S. MurtazaG. Therapeutic effects and safe uses of plant-derived polyphenolic compounds in cardiovascular diseases: A review.Drug Des. Devel. Ther.2021154713473210.2147/DDDT.S32723834848944
     [Google Scholar]
  53. SharmaS. YaduwanshiP.S. SanodiyaI.K. KumarM. SoniM. DwivediM. A mini review on health benefits of plant-based secondary metabolites.J. Pharm. Negat. Results202220225389539510.47750/pnr.2022.13.S10.655
     [Google Scholar]
  54. EllisonD.H. Clinical pharmacology in diuretic use.Clin. J. Am. Soc. Nephrol.20191481248125710.2215/CJN.0963081830936153
     [Google Scholar]
  55. PeirlinckM. CostabalF.S. YaoJ. GuccioneJ.M. TripathyS. WangY. OzturkD. SegarsP. MorrisonT.M. LevineS. KuhlE. Precision medicine in human heart modeling.Biomech. Model. Mechanobiol.202120380383110.1007/s10237‑021‑01421‑z33580313
     [Google Scholar]
  56. PereiraB.P. do ValeG.T. CeronC.S. The role of nitric oxide in renovascular hypertension: From the pathophysiology to the treatment.Naunyn Schmiedebergs Arch. Pharmacol.2022395212113110.1007/s00210‑021‑02186‑z34994823
     [Google Scholar]
  57. CarlströmM. Nitric oxide signalling in kidney regulation and cardiometabolic health.Nat. Rev. Nephrol.202117957559010.1038/s41581‑021‑00429‑z34075241
     [Google Scholar]
  58. AhmadA. DempseyS.K. DanevaZ. AzamM. LiN. LiP.L. RitterJ.K. Role of nitric oxide in the cardiovascular and renal systems.Int. J. Mol. Sci.2018199260510.3390/ijms1909260530177600
     [Google Scholar]
  59. CowleyA.W.Jr MoriT. MattsonD. ZouA.P. Role of renal NO production in the regulation of medullary blood flow.Am. J. Physiol. Regul. Integr. Comp. Physiol.20032846R1355R136910.1152/ajpregu.00701.200212736168
     [Google Scholar]
  60. SavedchukS. PhachuD. ShankarM. SparksM.A. Harrison-BernardL.M. Targeting glomerular hemodynamics for kidney potection.Adv. Kidney Dis. Health2023302718410.1053/j.akdh.2022.12.00336868736
     [Google Scholar]
  61. Krüger-GengeA. BlockiA. FrankeR.P. JungF. Vascular endothelial cell biology: An update.Int. J. Mol. Sci.20192018441110.3390/ijms2018441131500313
     [Google Scholar]
  62. SilvaR. Nitric oxide signaling and the cross talk with prostanoids pathways in vascular system.Med. Chem.2016134562710.2174/1573406412666161228115627
     [Google Scholar]
  63. LuoS. Caveolin-1 regulates cellular metabolism: A potential therapeutic target in kidney disease.Front. Pharmacol.20211276810010.2174/1573406412666161228115627
     [Google Scholar]
  64. ZhangY. LiuY. SunJ. ZhangW. GuoZ. MaQ. Arachidonic acid metabolism in health and disease.MedComm.202345e36310.1002/mco2.36337746665
     [Google Scholar]
  65. XavierF.E. Nitrergic perivascular innervation in health and diseases: Focus on vascular tone regulation.Acta Physiol. (Oxf.)20202301e1348410.1111/apha.1348432336027
     [Google Scholar]
  66. VerschurenE.H.J. CastenmillerC. PetersD.J.M. ArjonaF.J. BindelsR.J.M. HoenderopJ.G.J. Sensing of tubular flow and renal electrolyte transport.Nat. Rev. Nephrol.202016633735110.1038/s41581‑020‑0259‑832127698
     [Google Scholar]
  67. MandalA.K. MountD.B. The molecular physiology of uric acid homeostasis.Annu. Rev. Physiol.201577132334510.1146/annurev‑physiol‑021113‑17034325422986
     [Google Scholar]
  68. MaiuoloJ. OppedisanoF. GratteriS. MuscoliC. MollaceV. Regulation of uric acid metabolism and excretion.Int. J. Cardiol.201621381410.1016/j.ijcard.2015.08.10926316329
     [Google Scholar]
  69. JinM. YangF. YangI. YinY. LuoJ.J. WangH. YangX.F. Uric acid, hyperuricemia and vascular diseases.Front. Biosci.201217165666910.2741/395022201767
     [Google Scholar]
  70. AlbertD. ScudderP.N. BagleyP. SaagK.G. Vascular consequences of hyperuricemia and hypouricemia.Rheum. Dis. Clin. North Am.201945345346410.1016/j.rdc.2019.04.00531277755
     [Google Scholar]
  71. SachsL. BatraK.L. ZimmermannB. Medical implications of hyperuricemia.Med. Health R. I.2009921135335519999892
     [Google Scholar]
  72. AgnolettiD. CiceroA.F.G. BorghiC. The impact of uric acid and hyperuricemia on cardiovascular and renal systems.Cardiol. Clin.202139336537610.1016/j.ccl.2021.04.00934247750
     [Google Scholar]
  73. ZhangY. JinL. LiuJ. WangW. YuH. LiJ. ChenQ. WangT. Effect and mechanism of dioscin from Dioscorea spongiosa on uric acid excretion in animal model of hyperuricemia.J. Ethnopharmacol.2018214293610.1016/j.jep.2017.12.00429233733
     [Google Scholar]
  74. ZhaoH. HuangJ. MiaoL. YangY. XiaoZ. ChenQ. HuangQ. AiK. Toward Urease-free wearable artificial kidney: Widened interlayer spacing MoS2 nanosheets with highly effective adsorption for uremic toxins.Chem. Eng. J.202243813558310.1016/j.cej.2022.135583
     [Google Scholar]
  75. ShiC. ZhouZ. ChiX. XiuS. YiC. JiangZ. ChenR. ZhangL. LiuZ. Recent advances in gout drugs.Eur. J. Med. Chem.2023245Pt 111489010.1016/j.ejmech.2022.11489036335742
     [Google Scholar]
/content/journals/cmc/10.2174/0109298673300632240823061848
Loading
Diuretic and Anti-hyperuricemic Effects of Geranyl Acetate in Rats
Curr. Med. Chem. 33, 1551 (2026); https://doi.org/10.2174/0109298673300632240823061848
/content/journals/cmc/10.2174/0109298673300632240823061848
/content/journals/cmc/10.2174/0109298673300632240823061848
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): Antioxidant activity; gout; hypertension; hyperuricemia; natural products; nitric oxide; xanthine oxidase

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test